



2022 US Sustainability Highlights Report

Teva provides quality medicines, improving the lives of patients around the world. We manage non-financial areas that are important to our business and our stakeholders to ensure our company is sustainable, makes a meaningful impact and creates long-term value.



Our Footprint

Our vast presence, significant manufacturing capacity and diversified network help patients receive the medicines they need.



5,455
employees (full-time equivalents)



23
sites¹



10
states²

Our Medicines

We believe everyone, everywhere should have access to quality medicines. We develop and supply generic, biosimilar and innovative healthcare products, as well as finished doses and active pharmaceutical ingredients.



40+
innovative products³



400+
generic products manufactured in **1,300+** dosage strengths and package sizes³



1 of every 12
generic medicine prescriptions filled with a Teva product

Globally:

2,300+
products, including **2,088**
generic products



Leading supplier of quality medicines on the World Health Organization's (WHO) Essential Medicines List (EML)—manufacturing **49%** of medicines⁴ on this list of treatments for priority health needs



49
generic medicine approvals and **1** innovative medicine approval (sNDA)



20
generic medicine launches



Clinical trials conducted for:
29 innovative medicines
58 generic medicines

Our Economic Impact⁵

Teva's generic medicines generate savings for healthcare systems and help patients access treatments at lower costs, without compromising quality. We also create societal value as an employer and a manufacturer. Our spending and income creation initiate a production cycle that supports more jobs and further contributes to the economy.



Our generic medicines contributed to **\$36.6B** in savings



Our direct and spillover economic activity:
\$7.45B contributed to GDP⁶
\$2.71B generated in total labor income⁷
41,790 jobs supported (full-time equivalents)⁸



\$703M in Medicaid rebate savings across all 50 states in 2021

We have set global targets to guide our actions and hold us accountable to making progress. Some of these targets are tied to our financial strategy, including through sustainability-linked bonds valued at approximately **\$7.5B**. To learn more about our global sustainability efforts, including how we're delivering against our targets, see [Teva's 2022 ESG Progress Report](#).

Access to Medicines

Increasing access to medicines is fundamental to our mission to improve the lives of patients and is the basis of our business. We provide generic medicines, which are more affordable, as well as innovative medicines, which address unmet health needs.



Partnering to increase access to mental health care


In partnership with [Direct Relief](#) and the [National Association of Free & Charitable Clinics](#), we launched [Community Routes: Access to Mental Health Care](#), an innovative program to advance health equity by increasing access to care for uninsured and underserved patients suffering from depression and anxiety in California, Florida and New Jersey through donation of commonly-used generic medicines and grant funding to eligible free and charitable clinics.⁹ Medication donations were expanded to seven additional states in 2023.

In 2022:

Announced
11
grants to clinics

Donated
3.1M+
single doses of
medicine, worth **\$1.7M**

Community Routes: Access to Mental Health Care US Footprint



This program is providing:

\$2M
in grant funding
over **2** years

\$17M+
in medicines

with a potential reach of:

400+
clinics across
10 states

650,000+
uninsured patients¹⁰ a year

"All I saw was a totally black abyss of nothingness yawning ahead of me; I felt like my life was useless, worthless. That was my inner world for almost three years. Within two weeks of beginning therapy and taking the medicine, the darkness began to lift. Today I feel back to being my true self. I am regaining my creativity and enjoying learning new things again."

Mental health patient receiving a donated Teva medicine at a free and charitable clinic in Florida

Advancing digital healthcare

We conducted a [survey with the Morehouse School of Medicine](#), which found already vulnerable groups were disproportionately impacted by access to health barriers during the COVID-19 pandemic and that 84% of physicians reported an increase in new diagnoses of mental health conditions since the pandemic began. The survey also found that underserved communities often face challenges accessing digital healthcare due to lack of necessary technologies and broadband connectivity.

In 2022, we cofounded the [Digital Health for Equitable Health \(DHEH\) Alliance](#), bringing together multi-sector stakeholders to promote a more digitally inclusive and accessible society that will transform health delivery for underserved populations and advance equitable access to digital healthcare.

Pricing medicines

We recognize the connection between affordable medicines and optimal health and regularly review prices, considering market conditions, availability and production costs. Generic and innovative medicines are both part of a cycle of innovation, affordability and accessibility. Relative to 2021, in 2022:

3.74%
average list price increase
across our innovative
medicine portfolio

1.07%
average net price increase
across our innovative
medicine portfolio

Providing medicines to those in need



Medicine donations

38M+

single doses of medicine, valued at **\$60M**,¹¹ donated to US safety-net clinics through our nongovernmental organization (NGO) partners. Medicines also donated to **70+** countries.



Patient assistance programs

1.6M

units of medicine, worth **\$174M**,¹¹ provided through patient assistance programs, including the Teva Cares Foundation; these programs provide Teva medicines at no cost to patients who meet certain insurance and income criteria.



Emergency and disaster relief

Medicines donated to support those impacted by [Hurricane Ian](#) and the [Kentucky flooding](#) through Direct Relief.

Globally:

30.4M

doses of essential medicines—valued at **\$11.5M**—donated to [Ukrainian people](#), the largest donation from a pharmaceutical company at the time.




Inclusion and Diversity

By creating a welcoming culture, our employees feel heard, safe and respected, allowing them to be their full selves and do their best work. Diversity of thought and skill drives our collective creativity and success, allowing us to provide more quality medicines and reach more patients.



Maintaining a diverse workforce

We actively recruit candidates of different backgrounds.



We partner with Integrate Advisors—an organization that supports the placement of neurodivergent individuals—and with its help, we have already placed two individuals who support Teva’s document digitization process.


Celebrating diversity

Our employee resource groups (ERGs) are safe spaces for colleagues to explore their identities, build communities and celebrate their diverse cultures and backgrounds. These include:

- **Women@Teva**
- **Abilities**
- **Black Heritage**
- **Pride**
- **Asian Heritage**
- **MERGE (Multigenerational ERG)**
- **Hispanic/Latino Heritage**
- **Working Families**
- **Vets@Teva**
- **Men@Teva**

Working with diverse suppliers

We pursue business opportunities with small and diverse organizations. In 2022, our procurement spend with small and diverse businesses was more than 11.5%, and our small business supplier base increased by more than 55% from 2021.



Enhancing clinical trial diversity

Enrolling participants of diverse backgrounds in clinical trials helps us learn more about the safety and effectiveness of our medicines for a wider range of people. Our patient diversity site awareness vendor supports sites in increasing diversity in clinical trial recruitment.

We also introduced a race and ethnicity diversity plan for upcoming innovative clinical trials, with an emphasis on phases 2 and 3. For phases 1b to 3, we engaged patients and caregivers of various racial and ethnic backgrounds through patient advocacy groups.

Being recognized

Our efforts to foster an inclusive and diverse workplace have received top scores and recognition from the Corporate Equality Index, Disability Equality Index and Bloomberg Gender-Equality Index, as well as the Mansfield Rule: Legal Department Edition 2.0 Certification and ADP People at Work Award.




Environmental Sustainability

We mitigate our impact on the environment to improve the health of the planet, which is inherently linked to the health of those who inhabit it.



Minimizing our footprint

Our actions are primarily focused on climate action and resilience, responsible use of natural resources and minimizing effluents and waste. Since 2021, we:



Implementing environmental sustainability initiatives

We develop innovative projects to further reduce our footprint. We worked with the US Food and Drug Administration to create electronic medication guides for products, which each year results in:

3,000
ton reduction in paper used in Teva's packaging operations, equivalent to **72,000** trees

2,500
ton reduction in carbon emissions
\$3.5M
savings in materials spend

We also introduced an Energy Treasure Hunt program in line with the US Environmental Protection Agency's Energy Star program. Cross-functional teams searched our facilities for quick methods for saving energy. As a result, one of our manufacturing sites in Florida:

Replaced **3,000+** lightbulbs in laboratories, offices, production areas and warehouses

Reduced carbon emissions by approximately **880** tons for the year

Making changes at our local sites

Our local sites contribute to our environmental sustainability progress.

In **Davie, Florida**, our manufacturing site replaced industrial wastewater piping with above ground piping to avoid potential contamination of ground water.

In **West Chester, Pennsylvania**, our site transitioned from a chemically-intensive method of cooling tower maintenance to a natural Sphagnum moss-based system, resulting in significant reduction in treatment chemicals, backwash cycles and water usage, with a savings of 3.5 million gallons of water a year. Our site also encouraged biodiversity by removing non-native plant species and planting native species in 20% of established planting beds.

In **Edison, New Jersey**, we partnered with the landlord, who installed solar panels that generate clean power and reduce greenhouse gas emissions, resulting in energy savings for Teva.

Globally:

We have ambitious targets for reducing our environmental impact, and **our GHG emissions reduction targets were validated by the Science Based Targets initiative (SBTi)**, indicating they are grounded in science and aligned with global goals to combat climate change.

We partner to promote environmental education and dialogue, as well as to advance industry actions. We are a **founding member of the Antimicrobial Resistance (AMR) Action Fund and contributed \$400,000** to invest in new antimicrobial therapies and develop a sustainable antibiotic pipeline. We are

also a **member of the Pharmaceutical Product Stewardship Work Group (PPSWG)**, which provides infrastructure, guidance and subject matter expertise to support compliance and improve awareness of pharmaceutical disposal options.

We **joined the Energize program, a first-of-its-kind collaboration of pharmaceutical companies** to encourage and support suppliers to accelerate renewable energy adoption. This helps Teva's suppliers reduce their Scope 2 GHG emissions and in turn, Teva's Scope 3 emissions, as well as overall GHG emissions in the healthcare supply chain.

1. "Sites" includes commercial, R&D, manufacturing, distribution and Anda sites. 2. Teva had operations in California, Florida, Massachusetts, Mississippi, New Jersey, New York, Ohio, Pennsylvania, Virginia and Utah in 2022. 3. Data reflect products available in product catalog. 4. Number is based on INN 2022 total IQVIA data. 5. Results are not comparable to 2020 economic impact analysis due to different methodologies used. This analysis includes the economic impact of all Teva activities. Spillover data reflect domestic and foreign supply chain effects around the world. To learn more, see Teva's 2022 ESG Progress Report. 6. GDP (gross domestic product) refers to the economic value added and generated from Teva's activities. 7. Labor income refers to the sum of wages and salaries generated from, and as a result of, Teva's activities. 8. Jobs refers to those created by, and as a result of, Teva's activities. 9. This is one of eight access to medicines programs Teva committed to launch globally by 2025. 10. Data is not specific to those presenting with mental illness. 11. Value is based on wholesale acquisition cost (WAC). 12. "Other" includes undeclared and nonbinary employees. 13. HUBZone is a US Small Business Administration program for small companies that operates and employs people in Historically Underutilized Business Zones. 14. "Other" includes Caucasian male-owned small businesses, LGBTQ+-owned small businesses and disabled-owned small businesses.

Access to Medicines photo courtesy of Grace Medical Home in Orlando, Florida. All other photos are of Teva US employees.

